MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
125 hedge funds and large institutions have $2.34B invested in MyoKardia, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 51 increasing their positions, 38 reducing their positions, and 15 closing their positions.
194% more call options, than puts
Call options by funds: $6.24M | Put options by funds: $2.13M
34% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 38
33% more capital invested
Capital invested by funds: $1.75B → $2.34B (+$583M)
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
3% more funds holding
Funds holding: 121 → 125 (+4)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.6M |
| 2 |
BlackRock
New York
|
+$13.2M |
| 3 |
D.E. Shaw & Co
New York
|
+$8.72M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$8.62M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$16.4M |
| 2 |
DM
Deerfield Management
New York
|
-$14.2M |
| 3 |
SC
Samlyn Capital
New York
|
-$8.48M |
| 4 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
-$8.05M |
| 5 |
JP Morgan Chase
New York
|
-$7.38M |
MYOK Hedge Fund Activity: Q3 2018 in Review
125 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q3 2018, worth a combined $2.34B — up 33% from $1.75B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new MYOK positions and 15 closed out — a net gain of 4 holders — while 51 added to existing stakes and 38 trimmed.
The largest buyer was Vanguard Group, adding an estimated $43.6M. The largest seller was Millennium Management, cutting an estimated $16.4M.
- 125 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q3 2018, up from 121 in Q2 2018.
- Funds reported $2.34B of MyoKardia, Inc. Common Stock stock for Q3 2018, up 33% quarter-over-quarter.
- 19 funds opened new MyoKardia, Inc. Common Stock positions in Q3 2018 and 15 closed out, a net change of +4 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q3 2018 was Vanguard Group, an estimated $43.6M added.
- The largest MyoKardia, Inc. Common Stock seller in Q3 2018 was Millennium Management, an estimated $16.4M sold.
Based on aggregated 13F filings for Q3 2018.